speb/financial-data huggingface dataset:
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 1536000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 8363000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 1513000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 8394000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 1536000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 8394000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 1536000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 9806000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 8363000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 1513000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Net Interest Income: -2403000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -527000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: 9507000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Net Issuance Payments Of Debt: -10730000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Net Long Term Debt Issuance: -10955000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: -2403000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -527000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Net Other Investing Changes: 6092000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Net PPE: 51793000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 51793000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: -11106000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Net Short Term Debt Issuance: 225000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 26172000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 26172000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Revenue: 11375000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Revenue: 11375000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Assets: 2574000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 2574000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Liabilities: 1722000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 1722000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Non Current Prepaid Assets: 248000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 248000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 12300000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 3572000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Normalized Income: 5328021517.44
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Normalized Income: 1560237378.64
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: 10721000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Operating Income: 8051000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Operating Income: 2502000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Operating Revenue: 71921000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 19158000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 158396729.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 158396729.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 12000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 12000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 2021000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 2021000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: 148000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 148000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Intangible Assets: 10967000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 10967000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: -1558000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: 9000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 9000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Non Current Liabilities: 11375000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 11375000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: 568000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 119000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 14759000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 3667000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Payable: 5901000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 5901000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Properties: 24535000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 24535000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Receivables: 2392000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Receivables: 2392000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 124000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 124000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Other Special Charges: -4752000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Payables: 16154000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Payables: 16154000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 1294000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 1294000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Pretax Income: 9806000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 2060000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Properties: 0.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Purchase Of Investment: -14000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -11156000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Raw Materials: 5019000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Raw Materials: 5019000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 23170000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 6261000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 3686000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 952000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 65000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 65000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Repayment Of Debt: -11004000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Repurchase Of Capital Stock: -56000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 26000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 26000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Restructuring And Mergern Acquisition: 916000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Retained Earnings: 53018000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 53018000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Sale Of Investment: 9521000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 50000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 2058000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 4190000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Share Issued: 159281139.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 159281139.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Special Income Charges: 3595000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Special Income Charges: -33000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Stock Based Compensation: 43000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 62549000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 62549000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 26172000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 26172000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: 529021517.44
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: -8762621.36
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Tax Provision: 1443000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Tax Provision: 547000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.15
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.27
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Taxes Receivable: 180000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Taxes Receivable: 180000000.00
JUBLPHARMA.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -2384000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Assets: 127564000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 127564000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 84052000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 84052000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Debt: 27310000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 27310000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 62386000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 62386000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Total Expenses: 63870000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 16656000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 65178000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 65178000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 91792000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 91792000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 43532000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 43532000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Total Other Finance Cost: 194000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Total Tax Payable: 184000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 184000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Total Unusual Items: 3595000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items: -33000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: 3595000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: -33000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Tradeand Other Payables Non Current: 5356000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Tradeand Other Payables Non Current: 5356000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Treasury Shares Number: 884410.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Treasury Shares Number: 884410.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Work In Process: 3310000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Work In Process: 3310000000.00
JUBLPHARMA.NS balance_sheet (annual, 2025-03-31) — Working Capital: 14126000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 14126000000.00
JUBLPHARMA.NS income_statement (annual, 2025-03-31) — Write Off: 241000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 10692000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 18789000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 158551618.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 6.49
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 6182000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 981000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 981000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 159041731.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 6.47
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 1029000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — EBIT: 2034000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — EBITDA: 3015000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 12607000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 490000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 490000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Minority Interests: 4000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income: 1029000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 1029000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 1025000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 1029000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 1029000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 1025000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -490000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -490000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 3015000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 1029000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Operating Income: 1915000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 18789000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 120000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 4018000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 1544000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 6182000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 981000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Special Income Charges: 0.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 519000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.34
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 16874000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items: 0.00
JUBLPHARMA.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 0.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 12310000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 21161000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 158806818.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 3.52
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 7163000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 1207000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 1207000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 158806818.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 3.52
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 559000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — EBIT: 1495000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — EBITDA: 2702000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 13998000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 561000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 561000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Minority Interests: 1000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income: 559000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 559000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 558000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 559000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 559000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 558000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -561000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -561000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 3099000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 836900000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Operating Income: 1688000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 21161000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 205000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 4103000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 934000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 7163000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 1207000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: -397000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -119100000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 376000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.30
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 19473000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: -397000000.00
JUBLPHARMA.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -397000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — +Operating Expense: 47613000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 13364000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — +Total Revenue: 82250000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 22722000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 12341000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 12341000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 10696000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 10696000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Assets Held For Sale Current: 0.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Assets Held For Sale Current: 0.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 910000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 910000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 158145695.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 7.55
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 10883000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -14491000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 3952000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 3952000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 158000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 158000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 12671000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 12671000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 14865000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 14865000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Cash Dividends Paid: -795000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Inventory: -449000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Other Current Liabilities: 1791000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Payable: 1099000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Receivables: -1047000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: 1394000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Changes In Cash: 617000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Common Stock: 158000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 158000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Common Stock Dividend Paid: -795000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 70928000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 70928000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Common Stock Issuance: 10000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Common Stock Payments: -187000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 29615000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 29615000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 26443000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 7133000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Assets: 41093000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 41093000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 670000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 670000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Debt: 2478000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 2478000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 3148000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 3148000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 25389000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 25389000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 943000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 943000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Depreciation: 4404000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 4404000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 4404000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 1168000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 4404000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 1168000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 158776596.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 7.52
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 3985000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 1194000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — EBIT: 8259000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — EBIT: 2325000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — EBITDA: 12663000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — EBITDA: 3493000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Effect Of Exchange Rate Changes: 1171000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — End Cash Position: 12671000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: 949000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: -2223000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Gain Loss On Investment Securities: -31000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Gain Loss On Sale Of PPE: 55000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Goodwill: 28261000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Goodwill: 28261000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 41027000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 41027000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 69033000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 69033000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Gross Profit: 55807000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 15589000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Interest Expense: 2118000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 565000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 2118000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 565000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -2383000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 244000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Inventory: 12315000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 12315000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 103123000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 103123000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: -12600000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Investmentin Financial Assets: 910000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 910000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Investmentsin Associatesat Cost: 8000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Investmentsin Associatesat Cost: 8000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Issuance Of Capital Stock: 10000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Issuance Of Debt: 25713000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Long Term Capital Lease Obligation: 3282000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 3282000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Long Term Debt: 29717000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 29717000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 32999000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 32999000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Long Term Debt Issuance: 25713000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Long Term Debt Payments: -20132000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Long Term Equity Investment: 8000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Equity Investment: 8000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Long Term Provisions: 1595000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 1595000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Minority Interest: 28000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Minority Interest: 28000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Minority Interests: 10000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Minority Interests: 1000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Net Common Stock Issuance: -177000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Net Debt: 19524000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Net Debt: 19524000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: -64000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Net Income: 3985000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income: 1194000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 3985000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 1194000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: 3975000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 1193000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 3985000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 1194000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 3985000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 1194000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: 6141000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: 3975000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 1193000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Net Interest Income: -2118000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -565000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Net Investment Purchase And Sale: -165000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Net Issuance Payments Of Debt: 5016000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Net Long Term Debt Issuance: 5581000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: -2118000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -565000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Net Other Financing Charges: -3000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Net Other Investing Changes: 791000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Net PPE: 69033000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Net PPE: 69033000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Net PPE Purchase And Sale: -13470000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Net Short Term Debt Issuance: -565000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Net Tangible Assets: 29901000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 29901000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Assets: 2571000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 2571000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Liabilities: 2507000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 2507000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Normalized EBITDA: 13255000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 3630000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Normalized Income: 4368194919.39
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Normalized Income: 1286864204.55
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Operating Cash Flow: 12268000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Operating Income: 8194000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Operating Income: 2225000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Operating Revenue: 82250000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 22722000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 158387168.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 158387168.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Current Assets: 2490000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 2490000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 3403000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 3403000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 70770000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 70770000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Intangible Assets: 12766000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 12766000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: 2342000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Non Current Assets: 302000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 302000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Non Current Liabilities: 13720000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 13720000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 660000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 237000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Other Operating Expenses: 16749000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 4705000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Properties: 39418000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 39418000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Receivables: 19000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Receivables: 19000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 2194000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 2194000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Payables: 12542000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Payables: 12542000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Pretax Income: 6141000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Pretax Income: 1760000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Purchase Of Investment: -179000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Purchase Of PPE: -14491000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 26443000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 7133000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 4404000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 1168000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Repayment Of Debt: -20132000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Repurchase Of Capital Stock: -187000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Sale Of Investment: 14000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Sale Of PPE: 1021000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Share Issued: 159281139.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 159281139.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Special Income Charges: -592000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Special Income Charges: -137000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Stock Based Compensation: 118000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 70928000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 70928000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 29901000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 29901000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: -208805080.61
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: -44135795.45
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Tax Provision: 2166000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Tax Provision: 567000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.35
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.32
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Taxes Receivable: 708000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 708000000.00
JUBLPHARMA.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: -2094000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Assets: 155227000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 155227000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 100645000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 100645000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Debt: 36147000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 36147000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 70956000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 70956000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Total Expenses: 74056000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 20497000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 84271000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 84271000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 114134000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 114134000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 58882000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 58882000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Total Tax Payable: 201000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 201000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Total Unusual Items: -592000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items: -137000000.00
JUBLPHARMA.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: -592000000.00
JUBLPHARMA.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -137000000.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Treasury Shares Number: 893971.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Treasury Shares Number: 893971.00
JUBLPHARMA.NS balance_sheet (annual, 2026-03-31) — Working Capital: 15704000000.00
JUBLPHARMA.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: 15704000000.00
JUGI.L income_statement (annual, 2021-07-31) — +Operating Expense: 454000.00
JUGI.L income_statement (annual, 2021-07-31) — +Total Revenue: 141115000.00
JUGI.L balance_sheet (annual, 2021-07-31) — Accounts Payable: 1080000.00
JUGI.L balance_sheet (annual, 2021-07-31) — Additional Paid In Capital: 28798000.00
JUGI.L income_statement (annual, 2021-07-31) — Basic Average Shares: 78051669.00
JUGI.L income_statement (annual, 2021-07-31) — Basic EPS: 1.80
JUGI.L cash_flow (annual, 2021-07-31) — Beginning Cash Position: 5025000.00
JUGI.L balance_sheet (annual, 2021-07-31) — Capital Stock: 3981000.00
JUGI.L balance_sheet (annual, 2021-07-31) — Cash And Cash Equivalents: 3077000.00
JUGI.L balance_sheet (annual, 2021-07-31) — Cash Cash Equivalents And Federal Funds Sold: 3077000.00
JUGI.L cash_flow (annual, 2021-07-31) — Cash Dividends Paid: -4293000.00
JUGI.L cash_flow (annual, 2021-07-31) — Change In Accrued Expense: -18000.00
JUGI.L cash_flow (annual, 2021-07-31) — Change In Other Current Liabilities: 0.00
JUGI.L cash_flow (annual, 2021-07-31) — Change In Payable: 0.00
JUGI.L cash_flow (annual, 2021-07-31) — Change In Receivables: -116000.00
JUGI.L cash_flow (annual, 2021-07-31) — Change In Working Capital: -134000.00
JUGI.L cash_flow (annual, 2021-07-31) — Changes In Cash: -1950000.00
JUGI.L balance_sheet (annual, 2021-07-31) — Common Stock: 3981000.00
JUGI.L cash_flow (annual, 2021-07-31) — Common Stock Dividend Paid: -4293000.00
JUGI.L balance_sheet (annual, 2021-07-31) — Common Stock Equity: 346291000.00
JUGI.L income_statement (annual, 2021-07-31) — Diluted Average Shares: 78051669.00
JUGI.L income_statement (annual, 2021-07-31) — Diluted EPS: 1.80
JUGI.L income_statement (annual, 2021-07-31) — Diluted NI Availto Com Stockholders: 140647000.00
JUGI.L cash_flow (annual, 2021-07-31) — Dividend Received Cfo: 4414000.00
JUGI.L cash_flow (annual, 2021-07-31) — Effect Of Exchange Rate Changes: 2000.00
JUGI.L cash_flow (annual, 2021-07-31) — End Cash Position: 3077000.00
JUGI.L balance_sheet (annual, 2021-07-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 377140000.00
JUGI.L cash_flow (annual, 2021-07-31) — Financing Cash Flow: 9693000.00
JUGI.L cash_flow (annual, 2021-07-31) — Free Cash Flow: 1590000.00
JUGI.L cash_flow (annual, 2021-07-31) — Gain Loss On Investment Securities: -4414000.00
JUGI.L income_statement (annual, 2021-07-31) — Gain On Sale Of Security: 46235000.00
JUGI.L income_statement (annual, 2021-07-31) — General And Administrative Expense: 413000.00
JUGI.L income_statement (annual, 2021-07-31) — Interest Expense: 277000.00
JUGI.L income_statement (annual, 2021-07-31) — Interest Income: 4000.00
JUGI.L cash_flow (annual, 2021-07-31) — Interest Paid Cfo: -291000.00
JUGI.L cash_flow (annual, 2021-07-31) — Interest Received Cfo: 4000.00
JUGI.L balance_sheet (annual, 2021-07-31) — Invested Capital: 381291000.00
JUGI.L cash_flow (annual, 2021-07-31) — Investing Cash Flow: -13233000.00
JUGI.L balance_sheet (annual, 2021-07-31) — Investmentin Financial Assets: 377140000.00
JUGI.L balance_sheet (annual, 2021-07-31) — Investments And Advances: 377140000.00
JUGI.L cash_flow (annual, 2021-07-31) — Issuance Of Debt: 14000000.00
JUGI.L balance_sheet (annual, 2021-07-31) — Long Term Debt And Capital Lease Obligation: 35000000.00
JUGI.L cash_flow (annual, 2021-07-31) — Long Term Debt Issuance: 14000000.00
JUGI.L cash_flow (annual, 2021-07-31) — Long Term Debt Payments: 0.00
JUGI.L balance_sheet (annual, 2021-07-31) — Net Debt: 31923000.00
JUGI.L cash_flow (annual, 2021-07-31) — Net Foreign Currency Exchange Gain Loss: -5000.00
JUGI.L income_statement (annual, 2021-07-31) — Net Income: 140647000.00
JUGI.L income_statement (annual, 2021-07-31) — Net Income Common Stockholders: 140647000.00
JUGI.L income_statement (annual, 2021-07-31) — Net Income Continuous Operations: 140647000.00
JUGI.L income_statement (annual, 2021-07-31) — Net Income From Continuing And Discontinued Operation: 140647000.00
JUGI.L income_statement (annual, 2021-07-31) — Net Income From Continuing Operation Net Minority Interest: 140647000.00
JUGI.L cash_flow (annual, 2021-07-31) — Net Income From Continuing Operations: 140954000.00
JUGI.L income_statement (annual, 2021-07-31) — Net Income Including Noncontrolling Interests: 140647000.00
JUGI.L income_statement (annual, 2021-07-31) — Net Interest Income: -273000.00
JUGI.L cash_flow (annual, 2021-07-31) — Net Investment Purchase And Sale: -13233000.00
JUGI.L cash_flow (annual, 2021-07-31) — Net Issuance Payments Of Debt: 14000000.00
JUGI.L cash_flow (annual, 2021-07-31) — Net Long Term Debt Issuance: 14000000.00
JUGI.L cash_flow (annual, 2021-07-31) — Net Other Financing Charges: -14000.00
JUGI.L balance_sheet (annual, 2021-07-31) — Net Tangible Assets: 346291000.00
JUGI.L income_statement (annual, 2021-07-31) — Normalized Income: 140647000.00
JUGI.L cash_flow (annual, 2021-07-31) — Operating Cash Flow: 1590000.00
JUGI.L income_statement (annual, 2021-07-31) — Operating Revenue: 141115000.00
JUGI.L balance_sheet (annual, 2021-07-31) — Ordinary Shares Number: 78051669.00